Two Non-Hormonal Male Contraceptives Enter Phase II Clinical Trials

NEXT Life Sciences has advanced two non-hormonal male contraceptive options into Phase II clinical trials, marking progress in expanding birth control choices beyond condoms and vasectomy. The company's flagship product Plan A™ and its contraceptive pill NLS-133 are both in active clinical testing.

In 2025, NEXT Life Sciences' flagship product, Plan A™, a long-acting, non-hormonal, and reversible-on-demand option, proved its delivery device 100% successful in early trials in Australia and Canada. In October 2025, it entered Phase II clinical trials with the full Plan A™ contraceptive system.

NEXT Life Sciences is also pleased to reveal a male contraceptive solution for men and couples interested in on-demand solutions with NLS-133, a non-hormonal male contraceptive pill, designed to provide 24 hours of protection and for use as either an on-demand or daily pill. NLS-133 has begun a Phase II clinical trial where participants' semen levels are being evaluated after taking the non-hormonal contraceptive pill to further demonstrate the effectiveness of NLS-133.

The Chief Executive Officer stated that over 20 percent of women cannot tolerate hormonal birth control, in some cases with severe consequences, making it important that couples have multiple family planning options and particularly ones without hormones.

Currently, half of pregnancies worldwide remain unplanned, highlighting a persistent gap between available options and how people actually plan their lives. At the same time, the burden of contraception continues to fall almost entirely on women. Recent data shows that 50% of women experience side effects from birth control that are more severe than expected, further fueling this demand for better alternatives.

Research published in Andrology indicates that 7 in 10 men are willing to try new male contraceptive methods, signaling readiness for broader participation in family planning. Yet male options remain limited to condoms or vasectomy, leaving demand unmet. Over 17 million American men are actively seeking new contraceptive options and couples are asking for more shared responsibility in family planning.

To support future continued clinical development and expansion, NEXT Life Sciences is planning a Series A round in 2026, following an oversubscribed Seed round.

Plan A™ and NLS-133 are currently not approved by the FDA for commercial distribution.